Abstract
Autoimmune diseases primarily mediated by T-cells effect a significant proportion of the population and include common and distressing conditions such as diabetes, multiple sclerosis, inflammatory bowel disease, skin diseases and arthritis. Current treatments are restrictive in terms of range of options and side-effect profiles and new drugs and new approaches are always eagerly sought. With the T-cell antigen receptor (TCR) as a model system we have identified a new approach to inhibit T-cell activation. By means of peptides derived from the transmembrane TCR-alpha chain region we have shown that T-cells, the major effector cells of disease, can be inhibited in vitro and the immune responses leading to disease ameliorated in animal models.
The exact molecular mechanism of peptide action is still uncertain and assumed to involve a disturbance in transmembrane protein-protein interactions mediated by amino acid charges that disrupt normal signaling pathways. This chapter summarizes the results to date of TCR core peptide (CP); the most effective peptide noted so far, in terms of function, behavior in membranes and future development and application as a therapeutic agent. The lessons learned from this model can be applied to other multi-subunit receptors that serve critical cellular functions and open new doors for drug design, development and application.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Cohen-Kaminsky S, Jambou R Prospects for a T-cell receptor vaccination against myasthenia gravis. Expert Rev Vaccines 2005; 4(4):473–492.
Bluestone J, Tang Q. Therapeutic vaccination using CD4+ CD25+ antigen-specific regulatory T-cells. Proc Nad Acad Sci USA 2004; 101(Suppl 2): 14622–14626.
Kolier M. Targeted therapy in rheumatoid arthritis. Wiener Medizinische Wbchenschrift 2006; 156(1–2):53–60.
Griffin M, Hoiman P, Tang Q et al. Development and applications of surface-linked single chain antibodies against T-cell antigens. J Immunol Methods 2001; 248(1–2):77–90.
Manolios N, Collier S, Taylor J et al. T-cell antigen receptor transmembrane peptides modulate T-cell function and T-cell-mediated disease. Nat Med 1997; 3:84–88.
Amon MA, Ali M, Bender V et al. Lipidation and glycosylation of a T-cell antigen receptor (TCR) transmembrane hydrophobic peptide dramatically enhances in vitro and in vivo function. Biochim Biophys Acta—Mol Cell Res 2006; 1763(8):879–888.
Gollner GP, Muller G, Alt R et al. Therapeutic application of T-cell receptor mimic peptides or cDNA in the treatment of T-cell-mediated skin diseases. Gene Therapy 2000; 7:1000–1004.
Huynh NT. T-cell antigen receptor transmembrane peptides and their effects on B and Natural Killer Cells. Masters Thesis, University of Sydney, 2005.
Mahnke K, Qian Y, Knop J et al. Dendritic cells engineered to secrete a T-cell receptor mimic peptide, induce antigen-specific immunosuppression in vivo. Nat Biotech 2003; 21:903–908.
Mozsolits H, Aguilar M-I. Surface Plasmon Resonance Spectroscopy: An emerging tool for the study of peptide-membrane interactions. Biopolymers (Peptide Science) 2002; 66:3–18.
Shai Y. Mechanism of binding insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non selective membrane lytic peptides. Biochim Biophys Acta 1999; 1462:55–70.
Debet CM, Li SC. Peptides in membranes: Helicity and hydrophobicity. Biopolymers 1995; 37:295–318.
White SH, Wimley WC. Peptides in lipid bilayers: Structural and thermodynamic basis for partitioning and folding. Curr Opin Struct Biol 1994; 4:79–86.
Bender V, Ali M, Amon M et al. T-cell antigen receptor peptide-lipid membrane interactions using Surface Plasmon Resonance. J Biol Chem 2004; 279(52):54002–54007.
Ali M, De Planque M, Huynh N et al. Biophysical studies of transmembrane peptide derived from the T-cell antigen receptor. Lett Peptide Sci 2002; 8:227–233.
Wang X. Biological and biophysical properties of T-cell antigen receptor (TCR) transmembrane peptides in cell membranes. Masters Thesis Sydney, University of Sydney 2001.
Ali M, Salam NK, Amon MA et al. T-cell antigen receptor—Alpha chain transmembrane peptides: Correlation between structure and function. Int J Pept Res Ther 2006; 12:261–267.
Wang XM, Djordjevic JT, Bender V et al. T-cell antigen receptor (TCR) transmembrane peptides colocalise with TCR, not lipid rafts, in surface membranes. Cell Immunol 2002; 215:12–19.
Wang XM, Djordjevic JT, Kurosaka N et al. T-cell antigen receptor peptides inhibit signal transduction within the membrane bilayer. Clin Immunol 2002; 105:199
Huynh NT, Ffrench RA, Boadle RA et al. Transmembrane TCR peptides inhibit B and NK cell function. Immunology 2003; 108(4):458–464.
Vandebona H, Ali M, Amon M et al. Immunoreceptor transmembrane peptides and their effect on Natural Killer (NK) cell cytotoxicity. Protein Pept Lett 2006; 13(10):1017–1024.
Call ME, Pyrdol J, Wiedmann M et al. The organizing principle in the formation of the T-cell receptor-CD3 complex. Cell 2002; 111:967–979.
Call ME, Wucherpfennig KW. The T-cell receptor: Critical role of the membrane environment in receptor assembly and function. Annu Rev Immunol 2005; 23:101–125.
Sigalov A. Multi-chain immune recognition receptors: Spatial organization and signal transduction. Semin Immunol 2005; 17:51–64.
Manolios N, Li ZG. The T-cell antigen receptor beta chain interacts with the extracellular domain of CD3-gamma. Immunol Cell Biol 1995; 73:532–536.
Wang J-h, Lim K, Smolyar A et al. Atomic structure of an αβ T-cell receptor (TCR) heterodimer in complex with an antiTCR Fab fragment derived from a mitogenic antibody. EMBO J 1998; 17(1):10–26.
Ghendler Y, Smolyar A, Chang H-C et al. One of the CD3ɛ Subunits within a T-cell receptor complex lies in close proximity to the Cβ FG loop. J Exp Med 1998; 187(9):1529–1536.
Ali M, Amon M, Bender V et al. Hydrophobic transmembrane-peptide lipid conjugations enhance membrane binding and functional activity in T-cells. Bioconjug Chem 2005; 16(6):1556–1563.
Kim J, Shishido T, Jiang X et al. Phosphorylation, high ionic strength and calmodulin reverse the binding of MARCKS to phospholipid vesicles. J Biol Chem 1994; 269:28214–28219.
Wells XE, Bender VJ, Francis CL et al. Tris and the ready production of drug-fatty acyl conjugates. Drug Dev Res 1999; 46(3–4):302–308.
Blanchfield JT, Toth I. Modification of peptides and other drugs using lipoamino acids and sugars. Methods Mol Biol 2005; 298:45–61.
Melnyk RA, Partridge AW, Yip J et al. Polar residue tagging of transmembrane peptides. Biopolymers (Peptide Science) 2003; 71:675–685.
Collier S, Bolte A, Manolios N. Discrepancy in CD3-transmembrane peptide activity between in vitro and in vivo T-cell inhibition. Scand J Immunol 2006; 64(4):388–391.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Manolios, N., Ali, M., Amon, M., Bender, V. (2008). Therapeutic Application of Transmembrane T and Natural Killer Cell Receptor Peptides. In: Sigalov, A.B. (eds) Multichain Immune Recognition Receptor Signaling. Advances in Experimental Medicine and Biology, vol 640. Springer, New York, NY. https://doi.org/10.1007/978-0-387-09789-3_16
Download citation
DOI: https://doi.org/10.1007/978-0-387-09789-3_16
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-09788-6
Online ISBN: 978-0-387-09789-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)